While not statistically significant, the higher prevalence of TP53 mutations in the H/L cohort is noteworthy, as TP53 inactivation is associated with increased genomic instability, tumor aggressiveness, and chemoresistance in HCC. This evidence concerns the gene TP53 and neoplasm.